Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STRO
Strong SellSinkerSutro Biopharma, Inc. · Healthcare · United States · $339M · Avg Vol: $4M/d
9
StockRankGet insider-trade alerts
Q
16
V
26
M
40
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67.8M | 153.7M | 62.0M | 102.5M | 14.8% | 45.7M | 51.5M | -49.7% |
| EPS | -8.15 | -6.55 | -14.64 | -22.49 | — | -17.37 | -8.20 | — |
| Shares | 16.6M | 16.6M | 16.6M | 8.6M | -48.2% | — | — | — |
| Debt | 50.4M | 33.6M | 23.2M | 15.7M | -32.3% | 10.8M | — | — |
| Equity | 217.0M | 149.6M | 44.6M | -132.5M | -54.7% | — | — | — |
| Op CF | 3.5M | -111.6M | -191.5M | -177.2M | — | -145.2M | — | — |
| Inv CF | -35.0M | -3.9M | 218.5M | 45.0M | — | — | — | — |
| Fin CF | 48.3M | 137.6M | 94.1M | 44.0K | — | — | — | — |
Loading 1Y...
PRICE (1Y)-28.2%
SMA 50SMA 200
Close
$17.83
RSI (14)
24.5
52W High
$43.85
From 52W High
0.4%
SCORE BREAKDOWN
Quality
16
ROIC
-113.3%5.6
ROE
—N/A
GP/Assets
-57.0%0.8
Op. Margin
-301.7%12.1
FCF/Assets
-87.5%2.8
Piotroski
321.9
Int. Cover
-2.7x30.7
D/E Ratio
—N/A
Current Ratio
3.32x58.8
Value
26
P/E (TTM)
—N/A
EV/EBITDA
-1.5x25.0
P/FCF
—N/A
P/B
-3.2x25.0
P/S
7.3x32.3
Div Yield
—N/A
Momentum
40
52W High %
41%14.9
RS 6M
-40%19.4
SMA 50/200
1.06x69.6
EPS Rev 4W
+9.8%89.0
EPS Rev 12W
—N/A
EPS Improve
+64%62.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$339M
P/E (Forward)
-3.2x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STRO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STRO | Sutro Biopharma, Inc.(you) | $339M | 9 | Strong Sell |
| LYEL | Lyell Immunopharma, Inc. | $356M | 7 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 8 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $356M | 7 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $399M | 7 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 11 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%